PHIO vs. ALZN, REVB, GOVX, EVOK, BCEL, ARTL, CLVR, PHAS, ENSC, and LGVN
Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Alzamend Neuro (ALZN), Revelation Biosciences (REVB), GeoVax Labs (GOVX), Evoke Pharma (EVOK), Atreca (BCEL), Artelo Biosciences (ARTL), Clever Leaves (CLVR), PhaseBio Pharmaceuticals (PHAS), Ensysce Biosciences (ENSC), and Longeveron (LGVN). These companies are all part of the "pharmaceutical preparations" industry.
Phio Pharmaceuticals (NASDAQ:PHIO) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking.
Phio Pharmaceuticals' return on equity of -123.19% beat Alzamend Neuro's return on equity.
In the previous week, Phio Pharmaceuticals had 13 more articles in the media than Alzamend Neuro. MarketBeat recorded 16 mentions for Phio Pharmaceuticals and 3 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.19 beat Phio Pharmaceuticals' score of 0.39 indicating that Alzamend Neuro is being referred to more favorably in the news media.
Phio Pharmaceuticals presently has a consensus target price of $4.00, indicating a potential upside of 446.15%. Given Phio Pharmaceuticals' higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Alzamend Neuro.
Phio Pharmaceuticals has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500.
Phio Pharmaceuticals received 32 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 63.16% of users gave Phio Pharmaceuticals an outperform vote.
Alzamend Neuro is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 0.6% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Phio Pharmaceuticals beats Alzamend Neuro on 10 of the 14 factors compared between the two stocks.
Get Phio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phio Pharmaceuticals Competitors List
Related Companies and Tools
